Cite
HARVARD Citation
Naka, R. et al. (2022). Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone). Leukemia & lymphoma. 63 (6), pp. 1508-1511. [Online].